Tap - XTP

Latest news for Molson Coors Beverage (NYSE:TAP) Stock

Molson Coors Beverage

Molson Coors owns well-known beer brands including Miller, Coors, Blue Moon, and Carling, and ranks as the second-largest beer maker in both value and volume terms in the us, Canada, and the United Kingdom. Through licensing agreements, the firm also brews and distributes beer and hard seltzer under partner brands from Heineken, Anheuser-Busch InBev, Asahi, and Coca-Cola. The brewer uses independent distributors in the us given the three-tier distribution requirements, while using a combination of distributors and an in-house sales team in Canada and Europe. North America remains its largest market, contributing over 80% of total revenue.

Analyst Color

Equities

News

Upgrades

Price Target

Reiteration

Analyst Ratings

Trading Ideas

General

골드만삭스(Goldman Sachs)의 분석가 본니 헤르조그(Bonnie Herzog)는 최근 베버리지 바이트(Beverage Bytes)의 설문조사에서 맥주 유통업체들로부터 얻은 피드백을 바탕으로 몰슨 쿠어스 베버리지(NYSE:TAP)와 콘스텔레이션 브랜드(Constellation Brands Inc) (NYSE:STZ)에 대한 판단을 좀 더 긍정적이고, 보스톤 비어 컴퍼니(NYSE:SAM)에 대한 판단을 부정적으로 바꿨다.

골드만삭스는 몰슨 쿠어스와 컨스텔레이션 브랜드에 대해 더 긍정적 견해: 이유는?

Molson Coors Beverage Company Class B Common Stock

Molson Coors Beverage Co

Molson Coors Beverage Company Class A Common Stock

TAI PING CARPETS INTL by Tai Ping Carpets International

TRIPUTRA AGRO PERSADA TBK by TRIPUTRA AGRO PERSADA TBK PT

PT Triputra Agro Persada Tbk

Tapinator Inc

Tap Resources Inc

A recent study led by Dr. Erika Rosen of the Alcohol Research Group and RTI International&nbsp;and published in the Journal of Studies on Alcohol and Drugs, explores the differential impacts of alcohol, cannabis, and opioids on U.S. adults.
This research is significant for the cannabis industry as it highlights the relatively lower harms of cannabis compared to alcohol and opioids, presenting a strong case for cannabis-infused beverages as safer alternatives.
As consumer preferences shift towards healthier options, the cannabis beverage market stands to benefit from increased acceptance and potential regulatory ease, marking a promising growth area within the industry.
<h3>Impact Of Alcohol And Opioids</h3>
The study shows that over a third of U.S. adults have experienced harm from someone else&#39;s drinking. Specifically, 34.2% of respondents reported impacts from secondhand alcohol exposure, higher than harms from cannabis use, which was 5.5%. Harms from opioids were 7.6%. These harms include traffic accidents, and family, and financial issues, indicating the wide reach of these substances&#39; impact.
<h3>Cannabis: Comparatively Less Harmful</h3>
The research indicates that individuals who frequently use cannabis are less likely to cause secondhand harm than those who consume alcohol above low-risk guidelines or use opioids.
This <a href="https://www.jsad.com/doi/epdf/10.15288/jsad.23-00387?role=tab">data </a>suggests cannabis may have a less negative impact on bystanders, highlighting the need to reassess its societal and legal perceptions relative to more impactful substances like alcohol and opioids.
<h3>Demographic Disparities In Harm</h3>
The <a href="https://arg.org/news/alcohol-and-drug-use-cause-significant-harms-that-go-beyond-the-individual/">study highlights </a>demographic differences in experiencing these harms. Women, white individuals&nbsp;and those who are separated, divorced&nbsp;or widowed report higher instances of harm. Black respondents report fewer harms from secondhand alcohol or opioid use but more from cannabis, potentially due to more severe legal consequences and societal stigmatization.
<h3>Shift In Consumption: Cannabis Surpasses Alcohol in Daily Use</h3>
For the first time, daily cannabis consumption in the U.S. has <a href="https://www.benzinga.com/markets/cannabis/24/05/38976556/daily-cannabis-consumption-outpaces-daily-alcohol-use-in-the-us-for-the-first-time-new-study-sho">surpassed</a> daily alcohol use, with a new study revealing that 17.7 million Americans reported using marijuana daily or near-daily in 2022, compared to 14.7 million daily or near-daily alcohol consumers.
This shift underscores the growing market potential for <a href="https://www.benzinga.com/markets/cannabis/24/05/38566712/are-hemp-thc-beverages-competing-with-alcohol-experts-discuss-new-alternatives-for-adult-beverag">non-alcoholic cannabis products </a>as more consumers opt for healthier and socially acceptable alternatives to alcohol.
Hemp-based cannabis beverages present a promising alternative to alcohol, capitalizing on their <a href="https://www.benzinga.com/general/biotech/23/06/33036049/interstate-hemp-tapping-into-potential-of-nationwide-shipping-and-strategic-partnerships-for-mark">federally legal status</a> which allows nationwide distribution under the 2018 Farm Bill. These beverages appeal to a broad market by offering customizable <a href="https://www.benzinga.com/general/biotech/23/08/33035737/viral-on-tiktok-this-companys-success-paves-way-for-hemp-based-cannabis-beverages-across-state-li">non-alcoholic options</a> that deliver a <a href="https://www.benzinga.com/markets/cannabis/24/05/39069357/cannabis-now-surpasses-alcohol-this-trend-will-continue-for-decades-says-expert">mild buzz</a> without alcohol&#39;s adverse effects.
Some of the alcohol companies that have invested in cannabis include Constellation Brands (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/stz#NYSE">STZ</a>) and Molson Coors (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/tap#NYSE">TAP</a>), which have ventured into cannabis through significant investments in cannabis companies. Meanwhile, cannabis companies have also ventured into the alcohol industry; for example, Tilray (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tlry#NASDAQ">TLRY</a>) acquired Montauk Brewing Company.
Cannabis rescheduling seems to be right around the corner. Want to understand what this means for the future of the industry? Hear directly for top executives, investors, and policymakers at the 19th Benzinga Cannabis Capital Conference, coming to Chicago this Oct. 8-9.&nbsp;<a href="https://www.eventbrite.com/e/benzinga-capital-conference-cannabis-fall-2024-tickets-858948065787?aff=oddtdtcreator" rel="noopener noreferrer" target="_blank">Get your tickets now</a>&nbsp;before prices surge by following&nbsp;<a href="https://www.eventbrite.com/e/benzinga-capital-conference-cannabis-fall-2024-tickets-858948065787?aff=oddtdtcreator" rel="noopener noreferrer" target="_blank">this link</a>.
Photo: AI-Generated Image.&nbsp;

Cannabis

Market Summary

Penny Stocks

Guidance

Emerging Markets

Retail Sales

Small Cap

Markets

TLRY

Cannabis Found Less Harmful Than Alcohol In New Study: Where Is The Demand Heading? Investor Market Tips

Molson Coors Beverage Co Entered Certain Amendment No.1 & Extension Agreement Which Amends Certain Amended & Restated Credit Deal, Dated June 26, 2023, Amends Maturity Date Of Revolving Commitments Under Amended And Restated Credit Agreement To June 26, 2029

<a href="https://www.globenewswire.com/news-release/2024/06/04/2893189/0/en/Green-Thumb-Industries-Responds-to-Market-Rumors.html" title="https://www.globenewswire.com/news-release/2024/06/04/2893189/0/en/Green-Thumb-Industries-Responds-to-Market-Rumors.html">https://www.globenewswire.com/news-release/2024/06/04/2893189/0/en/Green-Thumb-Industries-Responds-to-Market-Rumors.html</a>

Green Thumb Industries Responds To Media Speculation; States Policy Is Not To Comment On Market Rumors

<a href="https://www.wsj.com/business/cannabis-producer-seeks-boston-beer-merger-b89e43c7?mod=latest_headlines" title="https://www.wsj.com/business/cannabis-producer-seeks-boston-beer-merger-b89e43c7?mod=latest_headlines">https://www.wsj.com/business/cannabis-producer-seeks-boston-beer-merger-b89e43c7?mod=latest_headlines</a>

'Cannabis Producer Seeks Boston Beer Merger' - WSJ

WIIM

Molson Coors Beverage shares are trading higher in sympathy with Boston Beer. Boston Beer gained on a report suggesting the company is in talks to sell itself to Suntory.

The most oversold stocks in the consumer staples sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the <a href="https://www.benzinga.com/topic/rsi">RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">Molson Coors Beverage Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAP#NYSE">TAP</a>)</h3>
<ul>
<li>On May 22, Molson Coors Beverage Company announced the pricing of its public offering of euro-denominated senior notes. The company's stock fell around 7% over the past month and has a <a href="https://www.benzinga.com/quote/TAP">52-week low of $52.60</a>.</li>
<li>RSI Value: 23.78</li>
<li>TAP Price Action: Shares of Molson Coors Beverage gained 0.4% to close at $53.22 on Thursday.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://pro.benzinga.com/dashboard">latest TAP news</a>.</li>
</ul>
<figure class="wp-block-image size-large"><a href="https://pro.benzinga.com/dashboard"><img loading="lazy" decoding="async" width="1024" height="560" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/31041808/Screenshot-2024-05-31-at-1.47.59-PM-1024x560.png" alt="" class="wp-image-364744" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/31041808/Screenshot-2024-05-31-at-1.47.59-PM-1024x560.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/31041808/Screenshot-2024-05-31-at-1.47.59-PM-300x164.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/31041808/Screenshot-2024-05-31-at-1.47.59-PM-768x420.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/31041808/Screenshot-2024-05-31-at-1.47.59-PM.png 1369w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
<h3 class="wp-block-heading">Adecoagro S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGRO#NYSE">AGRO</a>)&nbsp;&nbsp;&nbsp;&nbsp;</h3>
<ul>
<li>On May 16, Adecoagro posted better-than-expected quarterly sales. The company's stock fell around 10% over the past month. It <a href="ttps://www.benzinga.com/quote/AGRO">has a 52-week low</a> of $8.82.</li>
<li>RSI Value: 29.47</li>
<li>AGRO Price Action: Shares of Adecoagro gained 0.8% to close at $9.78 on Thursday.</li>
<li><a href="https://pro.benzinga.com/dashboard">Benzinga Pro's charting tool</a> helped identify the trend in Adecoagro's stock.</li>
</ul>
<figure class="wp-block-image size-large"><a href="https://pro.benzinga.com/dashboard"><img loading="lazy" decoding="async" width="1024" height="536" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/31041948/Screenshot-2024-05-31-at-1.49.40-PM-1024x536.png" alt="" class="wp-image-364748" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/31041948/Screenshot-2024-05-31-at-1.49.40-PM-1024x536.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/31041948/Screenshot-2024-05-31-at-1.49.40-PM-300x157.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/31041948/Screenshot-2024-05-31-at-1.49.40-PM-768x402.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/31041948/Screenshot-2024-05-31-at-1.49.40-PM.png 1380w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
<h3 class="wp-block-heading">The Kroger Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KR#NYSE">KR</a>)</h3>
<ul>
<li>On May 15, GoodRx Holdings announced a new direct contracting agreement with Kroger. The company's stock fell around 3% over the past five days and has a 52-week l<a href="https://www.benzinga.com/quote/KR">ow of $42.10.</a></li>
<li>RSI Value: 29.17</li>
<li>KR Price Action: Shares of Kroger rose 0.2% to close at $51.98 on Thursday.</li>
<li>Benzinga Pro's earnings calendar was used to track <a href="https://pro.benzinga.com/dashboard">Kroger's upcoming earnings report</a></li>
</ul>
<figure class="wp-block-image size-large"><a href="https://pro.benzinga.com/dashboard"><img loading="lazy" decoding="async" width="1024" height="561" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/31042054/Screenshot-2024-05-31-at-1.50.47-PM-1024x561.png" alt="" class="wp-image-364749" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/31042054/Screenshot-2024-05-31-at-1.50.47-PM-1024x561.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/31042054/Screenshot-2024-05-31-at-1.50.47-PM-300x164.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/31042054/Screenshot-2024-05-31-at-1.50.47-PM-768x421.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/31042054/Screenshot-2024-05-31-at-1.50.47-PM.png 1378w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
<h3 class="wp-block-heading">The Boston Beer Company, Inc.. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAM#NYSE">SAM</a>)</h3>
<ul>
<li>On April 25, Boston Beer reported better-than-expected first-quarter financial results and issued FY24 GAAP EPS guidance. &#8220;We were pleased to see flat depletion trends in the first quarter and to deliver revenue growth,&#8221; said Chairman and Founder Jim Koch. &#8220;We remain committed to investing across our portfolio of brands to drive long-term revenue growth while also expanding our margins.&#8221; The company's shares lost around 8% over the past month. The company's 52-week low is $254.40.</li>
<li>RSI Value: 29.37</li>
<li>SAM Price Action: Shares of Boston Beer rose 0.2% to close at $256.41 on Thursday.</li>
<li><a href="https://pro.benzinga.com/dashboard">Benzinga Pro's signals feature</a> notified of a potential breakout in Boston Beer shares.</li>
</ul>
<figure class="wp-block-image size-large"><a href="https://pro.benzinga.com/dashboard"><img loading="lazy" decoding="async" width="1024" height="577" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/31042205/Screenshot-2024-05-31-at-1.51.55-PM-1024x577.png" alt="" class="wp-image-364751" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/31042205/Screenshot-2024-05-31-at-1.51.55-PM-1024x577.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/31042205/Screenshot-2024-05-31-at-1.51.55-PM-300x169.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/31042205/Screenshot-2024-05-31-at-1.51.55-PM-768x433.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/31042205/Screenshot-2024-05-31-at-1.51.55-PM.png 1370w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
<h3 class="wp-block-heading">Hormel Foods Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HRL#NYSE">HRL</a>)</h3>
<ul>
<li>On May 30, Hormel Foods reported second-quarter fiscal 2024 sales declined 3% year-over-year to $2.887 billion, missing the consensus of $2.967 billion. "To reflect our solid first-half performance and our expectations for continued growth from our Foodservice and International segments, ongoing improvements across our supply chain, and further benefits from our transform and modernize initiative, we are updating our full-year earnings outlook," stated Jim Snee, chairman of the board, president and chief executive officer. The company's shares fell around 13% over the past five days. The company <a href="https://www.benzinga.com/quote/HRL">has a 52-week low</a> of $28.51.</li>
<li>RSI Value: 22.95</li>
<li>HRL Price Action: Shares of Hormel Foods fell 9.7% to close at $30.79 on Thursday.</li>
<li><a href="https://pro.benzinga.com/dashboard">Insider trades for Hormel Foods</a> were monitored using Benzinga Pro.</li>
</ul>
<figure class="wp-block-image size-large"><a href="https://pro.benzinga.com/dashboard"><img loading="lazy" decoding="async" width="1024" height="566" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/31042332/Screenshot-2024-05-31-at-1.53.25-PM-1024x566.png" alt="" class="wp-image-364752" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/31042332/Screenshot-2024-05-31-at-1.53.25-PM-1024x566.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/31042332/Screenshot-2024-05-31-at-1.53.25-PM-300x166.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/31042332/Screenshot-2024-05-31-at-1.53.25-PM-768x424.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/31042332/Screenshot-2024-05-31-at-1.53.25-PM.png 1378w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read More: <a href="https://www.benzinga.com/news/earnings/24/05/39104172/dell-asana-and-3-stocks-to-watch-heading-into-friday">Dell, Asana And 3 Stocks To Watch Heading Into Friday</a>

Long Ideas

Pre-Market Outlook

AGRO

Top 5 Defensive Stocks That May Explode This Quarter

Barclays analyst Lauren Lieberman maintains Molson Coors Beverage (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAP#NYSE">TAP</a>) with a Equal-Weight and lowers the price target from $62 to $55.

Barclays Maintains Equal-Weight on Molson Coors Beverage, Lowers Price Target to $55

Jefferies&nbsp;analyst Kaumil&nbsp;Gajrawala upgraded&nbsp;Boston Beer Company, Inc&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAM#NYSE">SAM</a>) to Buy from Hold,&nbsp;<a target="_blank" href="https://www.benzinga.com/quote/SAM/analyst-ratings" rel="noreferrer noopener">raising the price forecast to $360 from $335.</a>
Boston Beer has gone through several boom-bust cycles, but over time, value was created with higher highs and higher lows, the analyst writes.
The&nbsp;company&#8217;s beer and cider brands continue to decline, in line with the category. Collectively these brands are ~28%, Gajrawala notes.&nbsp;
However, reduced SKU complexity and refocused marketing could stabilize the business as category trends moderate. Given their relative size to Twisted/Truly, their headwinds should have minimal effect on total company trends&nbsp;going forward.
In addition, easing supply chain costs, higher in-house production, and efficiency measures support gross margin returning to normalized levels (high 40s %) over the medium term.&nbsp;
A clean balance sheet (no debt) and record cash levels increase the potential for capital returns if new initiatives do not gain traction, according to the analyst.
Per Gajrawala,&nbsp;with Truly trends stabilizing and Twisted continuing its recent growth trends, the company should return to volume growth for the first time since 2021.
Overall, the analyst raised the company&#8217;s full-year 2024 sales/EBITDA outlook by +1% and +3%,&nbsp;respectively.
The analyst applauds the company&#8217;s margin outlook and multiple expansions on&nbsp;return to volume&nbsp;growth and decreased volatility.
According to&nbsp;<a target="_blank" href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw" rel="noreferrer noopener">Benzinga Pro</a>, SAM stock has lost 9% in the past year.&nbsp;
Gajrawala&nbsp;reiterated the Buy rating on&nbsp;Constellation Brands, Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STZ#NYSE">STZ</a>), l<a target="_blank" href="https://www.benzinga.com/quote/STZ/analyst-ratings" rel="noreferrer noopener">owering&nbsp;the price target to $311 from $314.</a>
The analyst lowered the first quarter and FY25 sales outlook by -1% and &lt;-1% and EBITDA by -3% and -1%, respectively, given recent weakness.&nbsp;However, distributors remain bullish on Constellation. The analyst&#8217;s survey supports ~7%-9% org sales growth in their beer business.
Gajrawala reiterated&nbsp;Hold&nbsp;rating&nbsp;on&nbsp;Molson Coors Beverage Company&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAP#NYSE">TAP</a>),&nbsp;<a target="_blank" href="https://www.benzinga.com/quote/TAP/analyst-ratings" rel="noreferrer noopener">with&nbsp;forecast&nbsp;of&nbsp;$62.00.</a>
The analyst lowered CY24 sales &lt;-1% and EBITDA by -1%, given confirmed lower space gains, ABI momentum, and margin deleverage.
Price Action: TAP shares are trading lower by 1.45% to $57.89 at last check Tuesday, while STZ shares are trading lower by 2.2% to $253.07 and SAM shares are trading higher by 0.29% to $284.64.
Photo via Shutterstock

Boston Beer Company Gets A Spicy Buy Upgrade From Analyst Amid Other Beer Brands - Read Why

Barclays analyst Lauren Lieberman maintains Molson Coors Beverage (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAP#NYSE">TAP</a>) with a Equal-Weight and lowers the price target from $67 to $62.

Barclays Maintains Equal-Weight on Molson Coors Beverage, Lowers Price Target to $62

The most oversold stocks in the consumer staples sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the &lt;a href=&#8221;https://www.benzinga.com/topic/rsi&#8221;> <a href="https://www.benzinga.com/topic/rsi">RSI is below 30&lt;</a>/a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
Medifast, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MED#NYSE">MED</a>)
<ul>
<li>On April 29, Medifast reported mixed first-quarter financial results. &#8220;Fast paced medical innovation is providing greater access to medical weight loss solutions than ever before. We are transforming our OPTAVIA offer to include comprehensive support for consumers who wish to use GLP-1 medical weight loss solutions on their individual journeys to sustainable healthy lifestyles, Chairman &amp; Chief Executive Officer. The company's stock fell around 21% over the past five days and has a <a href="https://www.benzinga.com/quote/MED">52-week low of $25.92</a>.</li>
<li>RSI Value: 28.64</li>
<li>MED Price Action: Shares of Medifast fell 4.3% to close at $26.36 on Wednesday.</li>
</ul>
<h3 class="wp-block-heading">Safety Shot, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHOT#NASDAQ">SHOT</a>)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</h3>
<ul>
<li>On April 9, Safety Shot said the Nelk Boys have joined forces with Safety Shot as brand ambassadors. The company's stock fell around 35% over the past month. It <a href="https://www.benzinga.com/quote/SHOT">has a 52-week lo</a>w of $0.3050.</li>
<li>RSI Value: 29.61</li>
<li>SHOT Price Action: Shares of Safety Shot fell 9.2% to close at $1.39 on Wednesday.</li>
</ul>
<h3 class="wp-block-heading">Molson Coors Beverage Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAP#NYSE">TAP</a>)</h3>
<ul>
<li>On April 30, Molson Coors Beverage reported first-quarter FY24 sales growth of 10.7% year-on-year to $2.60 billion, beating the analyst consensus estimate of $2.50 billion. "Strong America's volume and favorable net pricing across both business units resulted in double-digit top-line growth while volume leverage and ongoing cost savings drove meaningful margin expansion in the quarter," said CFO Tracey Joubert. The company's shares fell around 11% over the past five days and has a 52-week <a href="https://www.benzinga.com/quote/TAP">low of $55.67</a>.</li>
<li>RSI Value: 22.34</li>
<li>TAP Price Action: Shares of Molson Coors Beverage fell 0.3% to close at $57.08 on Wednesday.</li>
</ul>
<h3 class="wp-block-heading">Australian Oilseeds Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COOT#NASDAQ">COOT</a>)</h3>
<ul>
<li>On April 25, Australian Oilseeds secured contracts with Woolworths and Costco for non-GMO cold-pressed oils. The company's shares lost around 7% over the past five days. The company's 52-week low is $1.14.</li>
<li>RSI Value: 28.98</li>
<li>COOT Price Action: Shares of Australian Oilseeds Holdings rose 1.1% to close at $1.3350 on Wednesday.</li>
</ul>

COOT

SHOT

Top 4 Defensive Stocks You'll Regret Missing This Quarter

During the last three months, 12 analysts shared their evaluations of Molson Coors Beverage (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAP#NYSE">TAP</a>), revealing diverse outlooks from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">8</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $64.17, a high estimate of $75.00, and a low estimate of $53.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 2.24%. 
<img src="https://www.benzinga.com/files/images/story/2024/1714590096_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
A comprehensive examination of how financial experts perceive Molson Coors Beverage is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Filippo Falorni</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Sell</td>
<td>$53.00</td>
<td>$56.00</td>
</tr>
<tr>
<td>Peter Grom</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$64.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Bryan Spillane</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$62.00</td>
<td>$72.00</td>
</tr>
<tr>
<td>Andrea Teixeira</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$60.00</td>
<td>$66.00</td>
</tr>
<tr>
<td>Robert Ottenstein</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$68.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Filippo Falorni</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Sell</td>
<td>$56.00</td>
<td>$66.00</td>
</tr>
<tr>
<td>Steve Powers</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Hold</td>
<td>$65.00</td>
<td>$64.00</td>
</tr>
<tr>
<td>Filippo Falorni</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$66.00</td>
<td>$63.00</td>
</tr>
<tr>
<td>Lauren Lieberman</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$67.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Bonnie Herzog</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$75.00</td>
<td>$66.00</td>
</tr>
<tr>
<td>Michael Lavery</td>
<td>Piper Sandler</td>
<td>Announces</td>
<td>Neutral</td>
<td>$69.00</td>
<td>-</td>
</tr>
<tr>
<td>Lauren Lieberman</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$65.00</td>
<td>$64.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Molson Coors Beverage. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Molson Coors Beverage compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Molson Coors Beverage's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Molson Coors Beverage's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/TAP/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Molson Coors Beverage analyst ratings.</a>
<h2>Get to Know Molson Coors Beverage Better</h2>
Molson Coors owns well-known beer brands including Miller, Coors, Blue Moon, and Carling, and ranks as the second-largest beer maker in both value and volume terms in the us, Canada, and the United Kingdom. Through licensing agreements, the firm also brews and distributes beer and hard seltzer under partner brands from Heineken, Anheuser-Busch InBev, Asahi, and Coca-Cola. The brewer uses independent distributors in the us given the three-tier distribution requirements, while using a combination of distributors and an in-house sales team in Canada and Europe. North America remains its largest market, contributing over 80% of total revenue.
<h3>Molson Coors Beverage: Delving into Financials</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Molson Coors Beverage's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 6.13% as of 31 December, 2023, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Consumer Staples sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of 3.7%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 0.78%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Molson Coors Beverage's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 0.39%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Molson Coors Beverage's debt-to-equity ratio is below the industry average at 0.48, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>How Are Analyst Ratings Determined?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Forecasting The Future: 12 Analyst Projections For Molson Coors Beverage

Citigroup analyst Filippo Falorni maintains Molson Coors Beverage (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAP#NYSE">TAP</a>) with a Sell and lowers the price target from $56 to $53.

Citigroup Maintains Sell on Molson Coors Beverage, Lowers Price Target to $53

UBS analyst Peter Grom maintains Molson Coors Beverage (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAP#NYSE">TAP</a>) with a Neutral and lowers the price target from $70 to $64.

UBS Maintains Neutral on Molson Coors Beverage, Lowers Price Target to $64

B of A Securities analyst Bryan Spillane maintains Molson Coors Beverage (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAP#NYSE">TAP</a>) with a Neutral and lowers the price target from $72 to $62.

B of A Securities Maintains Neutral on Molson Coors Beverage, Lowers Price Target to $62

JP Morgan analyst Andrea Teixeira maintains Molson Coors Beverage (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAP#NYSE">TAP</a>) with a Neutral and lowers the price target from $66 to $60.

JP Morgan Maintains Neutral on Molson Coors Beverage, Lowers Price Target to $60

Evercore ISI Group analyst Robert Ottenstein maintains Molson Coors Beverage (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAP#NYSE">TAP</a>) with a Outperform and lowers the price target from $70 to $68.

Evercore ISI Group Maintains Outperform on Molson Coors Beverage, Lowers Price Target to $68

Shares of H&amp;E Equipment Services, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HEES#NASDAQ">HEES</a>) fell sharply during Tuesday's session following <a href="https://www.benzinga.com/quote/HES/earnings">mixed first-quarter results</a>.
H&amp;E Equipment posted GAAP earnings of 71 cents per share, versus market estimates of 77 cents per share. The company's quarterly sales came in at $371.357 million versus expectations of $352.518 million, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
H&amp;E Equipment Services shares dipped 18.2% to $48.45 on Tuesday.
Here are some other stocks moving in today&#8217;s mid-day session.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Akili, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKLI#NASDAQ">AKLI</a>) shares jumped 67.2% to $0.3927 after the company announced Shionogi has canceled and forgiven a $5.0 million long-term debt obligation and agreed to make certain payments for SDT-001.</li>
<li>AGBA Group Holding Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGBA#NASDAQ">AGBA</a>) gained 57.5% to $3.70 after the company highlighted plans for its previously-announced merger with Triller.</li>
<li>Cyclacel Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) climbed 55.4% to $2.12 after falling over 9% on Monday.</li>
<li>Global Mofy Metaverse Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GMM#NASDAQ">GMM</a>) shares gained 50.2% to $1.40 after the company&#8217;s Gauss AI teamed with Heartdub to develop the Gausspeed generative AI platform.</li>
<li>GeneDx Holdings Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WGS#NASDAQ">WGS</a>) rose 40.8% to $15.49 after the company reported better-than-expected first-quarter financial results and raised its FY2024 sales guidance.</li>
<li>Eliem Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELYM#NASDAQ">ELYM</a>) gained 39.4% to $7.00.</li>
<li>Swvl Holdings Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWVL#NASDAQ">SWVL</a>) surged 29.8% to $13.14 after announcing results for the fiscal year 2023.</li>
<li>Next.e.GO N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EGOX#NASDAQ">EGOX</a>) gained 26.4% to $0.0349.</li>
<li>Blend Labs, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLND#NYSE">BLND</a>) shares climbed 25.8% to $2.83 after the company announced a strategic partnership with Haveli Investments, including a $150 million investment.</li>
<li>Daré Bioscience, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DARE#NASDAQ">DARE</a>) rose 24.2% to $0.3460 after the XOMA acquired an economic interest in the company&#8217;s women&#8217;s health assets. Also, the company announced that the transaction allows it to focus on advancing Phase 3 first-in-category women&#8217;s health product candidates.</li>
<li>LendingTree, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TREE#NASDAQ">TREE</a>) gained 24.2% to $46.39 after the company beat first-quarter estimates and issued strong guidance.</li>
<li>MIND Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIND#NASDAQ">MIND</a>) rose 24% to $5.85 following quarterly results.</li>
<li>Mullen Automotive, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MULN#NASDAQ">MULN</a>) gained 19.8% to $6.85.</li>
<li>Harmonic Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HLIT#NASDAQ">HLIT</a>) rose 19.2% to $11.19 following a first-quarter revenue beat.</li>
<li>Marin Software Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRIN#NASDAQ">MRIN</a>) rose 18.8% to $3.1002 after the company announced the launch of its AI-powered Anomaly Detector.</li>
<li>ATI Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATI#NYSE">ATI</a>) gained 15.5% to $59.94 following upbeat quarterly results.</li>
<li>Clearwater Paper Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLW#NYSE">CLW</a>) gained 15.2% to $46.88 following better-than-expected earnings.</li>
<li>LSB Industries, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LXU#NYSE">LXU</a>) rose 13.4% to $9.32 following strong quarterly earnings.</li>
<li>SES AI Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SES#NYSE">SES</a>) gained 13.3% to $1.53.</li>
<li>E2open Parent Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ETWO#NYSE">ETWO</a>) rose 12.5% to $4.7950 following upbeat results.</li>
<li>Sensata Technologies Holding plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ST#NYSE">ST</a>) shares climbed 12.1% to $40.04 as the company reported stronger-than-expected results for its first quarter on Monday. The company said Jeff Cote will retire as CEO and President. Sensata said it sees second-quarter adjusted earnings of 89 cents to 95 cents per share on revenue of $1.025 billion to $1.055 billion.</li>
<li>Addex Therapeutics Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADXN#NASDAQ">ADXN</a>) jumped 10.3% to $8.31. Addex shares dipped 53% on Monday after the company announced the Phase 2 ADX71149 epilepsy study did not achieve statistical significance for the primary endpoint of time for patients to reach baseline seizure count when ADX71149 was added to standard of care.</li>
<li>AgEagle Aerial Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UAVS#NASDAQ">UAVS</a>) gained 10.4% to $0.77. AgEagle announced $3.4 million drone sale to French Army.</li>
<li>Tenet Healthcare Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) rose 9.2% to $108.28 after the company reported better-than-expected first quarter earnings and issued strong guidance.</li>
<li>Brinker International, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EAT#NYSE">EAT</a>) gained 7.5% to $53.38 after the company reported strong third-quarter financial results and raised FY24 guidance.</li>
<li>Eli Lilly and Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) rose 6.6% to $785.51 after the company raised its FY24 revenue guidance.</li>
<li>3M Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMM#NYSE">MMM</a>) gained 5.5% to $97.25 following a first-quarter earnings beat.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Lichen China Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LICN#NASDAQ">LICN</a>) fell 30.6% to $1.4127 after surging 48% on Monday.</li>
<li>Cemtrex, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CETX#NASDAQ">CETX</a>) declined 29.7% to $1.25.</li>
<li>Chegg, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHGG#NYSE">CHGG</a>) shares fell 26.1% to $5.30 after the company posted first-quarter results and named Nathan Shultz as CEO.</li>
<li>NRx Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRXP#NASDAQ">NRXP</a>) dipped 25% to $2.6592 after the company announced findings from its Phase 2b/3 trial of NRX-101 vs. Lurasidone.</li>
<li>Bakkt Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BKKT#NYSE">BKKT</a>) fell 23.5% to $7.62. Bakkt Holdings is expected to release its first quarter 2024 earnings on Tuesday, May 14.</li>
<li>Medifast, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MED#NYSE">MED</a>) shares declined 22.6% to $27.50 after the company reported mixed first-quarter financial results.</li>
<li>Vince Holding Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VNCE#NYSE">VNCE</a>) were down 21.4% to $1.6536 after the company posted fourth-quarter results.</li>
<li>NewGenIvf Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIVF#NASDAQ">NIVF</a>) fell 20.1% to $1.63.</li>
<li>Top Wealth Group Holding Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWG#NASDAQ">TWG</a>) dipped 18% to $1.14.</li>
<li>MicroStrategy Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) declined 16.4% to $1,081.53 after the company reported worse-than-expected financial results for the first quarter.</li>
<li>Safe &amp; Green Holdings Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGBX#NASDAQ">SGBX</a>) fell 16% to $0.1185 after declining 4% on Monday.</li>
<li>ArcBest Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARCB#NASDAQ">ARCB</a>) declined 15.8% to $108.96 after the company reported worse-than-expected first quarter adjusted EPS results.</li>
<li>CECO Environmental Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CECO#NASDAQ">CECO</a>) fell 15% to $21.59 after the company reported worse-than-expected first-quarter sales results.</li>
<li>GE HealthCare Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEHC#NASDAQ">GEHC</a>) declined 13.2% to $77.22 following a first-quarter earnings miss.</li>
<li>Coursera, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COUR#NYSE">COUR</a>) shares declined 13.1% to $10.34 after the company reported mixed first-quarter financial results and issued FY24 revenue guidance below estimates.</li>
<li>Complete Solaria, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSLR#NASDAQ">CSLR</a>) fell 12.5% to $0.6393. Complete Solaria shares jumped 92% on Monday after the company named T.J. Rodgers as CEO.</li>
<li>Transocean Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RIG#NYSE">RIG</a>) fell 11% to $5.18 after the company reported worse-than-expected quarterly sales results.</li>
<li>Warner Bros. Discovery, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBD#NASDAQ">WBD</a>) declined 9.3% to $7.39 on reports NBCUniversal is preparing an offer that could take NBA rights from TNT.</li>
<li>F5, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFIV#NASDAQ">FFIV</a>) fell 7.6% to $168.36. F5 reported upbeat earnings for its second quarter, but issued weak forecast for the third quarter.</li>
<li>Molson Coors Beverage Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAP#NYSE">TAP</a>) declined 7.5% to $58.80 following quarterly results.</li>
<li>The Macerich Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MAC#NYSE">MAC</a>) fell 7.4% to $14.82 following quarterly earnings.</li>
<li>Yum China Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YUMC#NYSE">YUMC</a>) shares declined 7.3% to $37.13. Yum China posted upbeat earnings for its first quarter, while sales missed expectations.</li>
<li>Rambus Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMBS#NASDAQ">RMBS</a>) shares declined 7.3% to $56.10 following first-quarter results.</li>
</ul>
Now Read This: <a href="http://Domino's Pizza To Rally Over 10%? Here Are 10 Top Analyst Forecasts For Tuesday">Domino&#8217;s Pizza To Rally Over 10%? Here Are 10 Top Analyst Forecasts For Tuesday</a>

Intraday Update

Movers

ADXN

AGBA

AKLI

ARCB

Bakkt Holdings, Inc. Class A Common Stock

BKKT

BLND

CECO

CETX

CHGG

COUR

CSLR

CYCC

DARE

EGOX

ELYM

ETWO

FFIV

GEHC

HEES

HLIT

LICN

MIND

MRIN

MSTR

MULN

NIVF

NRXP

RMBS

SGBX

SWVL

TREE

UAVS

VNCE

YUMC

Why H&E Equipment Services Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

Molson Coors Beverage Company&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAP#NYSE">TAP</a>) reported first-quarter FY24 sales growth of 10.7% year-on-year to $2.60 billion,<a target="_blank" href="https://www.benzinga.com/pressreleases/24/04/b38514315/molson-coors-beverage-company-reports-2024-first-quarter-results" rel="noreferrer noopener">&nbsp;beating the analyst consensus estimate of $2.50 billion</a>.
The revenue increase was driven by higher financial volumes, favorable price and sales mix&nbsp;and&nbsp;favorable foreign currency impacts.
Net sales from the Americas segment increased 10.6% on a reported and constant currency basis.
Net sales from&nbsp;EMEA&nbsp;&amp; APAC segment jumped 10.9%, driven by favorable price and sales mix&nbsp;as well as&nbsp;favorable foreign currency impacts, partially offset by slightly unfavorable financial volumes.
Adjusted EPS of $0.95&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">beat the analyst consensus estimate of $0.74.&nbsp;</a>
Underlying&nbsp;cost of goods sold (COGS) per hectoliter increased&nbsp;0.9% in constant currency.
Gross profit climbed 25% Y/Y to $963.5 million. Operating income for the quarter jumped to $314.3 million, with a margin of 10.3%.
Molson Coors Beverage held $458.4 million in cash and equivalents as of March-end. Operating cash flow for the three months totaled $25.4 million.
&#8220;Strong America&#8217;s volume and favorable net pricing across both business units resulted in double-digit top-line growth while volume leverage and ongoing cost savings drove meaningful margin expansion in the quarter,&#8221; said CFO Tracey Joubert.
Outlook: Molson Coors reaffirmed its FY24 net sales outlook at a low single-digit increase <a href="https://www.benzinga.com/calendars/guidance">versus 2023 on a constant currency basis.</a>
Molson sees FY24 underlying diluted earnings per share:&nbsp;mid single-digit&nbsp;increase compared to 2023.
TAP continues to expect underlying free cash flow of $1.2 billion, plus or minus 10%&nbsp;and&nbsp;capital expenditures of $700 million, plus or minus 5%.
Price Action: TAP shares traded lower by 7.57% at $58.75 at the last check Tuesday.
Photo via Shutterstock

Earnings

Molson Coors Beverage Shares Take A Hit Despite Q1 Beat - What's Going On?

Molson Coors Exec Says The Year Did Not Start Off That Well From An Industry Point Of View; The Year Did Not Start Off Well Broadly Because Of Weather Conditions Across The Country; April Has Been "Pretty Choppy" From An Industry Point Of View

Molson Coors Exec Says Cautious About Current Trends In The Industry; U.S. Beer Category Has Been Challenged So Far This Year; "While We Did See Some Improvement In March, There Was Also Volatility In The Industry And Mismatched Weeks Such As Easter"; Retailers Have Allocated Around 13% More Space For Coors Light And Miller Lite In The U.S. During Spring Resets

Anheuser-Busch InBev: Though The Boycott Has Eased, It Is Still Overvalued

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
It&rsquo;s true that, with the interest rate on 10-year Treasury bonds still trading around 4.2%, stock dividends aren&rsquo;t nearly as important or valuable as they once were. After all, a risk-free yield of 4.2% makes even 5% dividend yields look unimpressive. And it is possible to buy low-risk corporate bonds that yield 6%-plus. Still, high-quality stocks with significant dividend yields offer a combination of yields and high, potential capital appreciation that bonds cannot match. 



Moreover, recent economic data suggests that inflation is headed sharply downward, a trend that should enable the Federal Reserve to cut interest rates rather sharply in the next year. As a result, interest rates are likely headed down, and the stock market appears to be poised for further gains. Given this outlook, it&rsquo;s a very good time to buy top-notch <a href="https://investorplace.com/stock-types/dividend-stocks/">dividend stocks</a> that can also benefit from the stock market&rsquo;s gains going forward.



<h2>Verizon Communications (VZ)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2024/01/vz1600-300x169.png" alt="Verizon Retail Location. Verizon delivers wireless, high-capacity fiber optics and 5G communications. VZ stock"><div>Source: RAMAN SHAUNIA / Shutterstock.com</div></div>Verizon (NYSE:<a href="https://investorplace.com/stock-quotes/vz-stock-quote/">VZ</a>) has <a href="https://finance.yahoo.com/quote/VZ/">a generous dividend yield </a>of 6.7%. What&rsquo;s more, the company is starting to benefit from price increases that it implemented in March. And despite those price hikes, it added a net total of 253,000 retail postpaid phone customers in Q1. Moreover, the company could get a <a href="https://www.google.com/search?q=u.s.+cellular+acquired&amp;sca_esv=cff19ea8ba3a868e&amp;sca_upv=1&amp;sxsrf=ADLYWIJj8Z1ZXZ55wd4ZDsFEFPcGeYEHMg%3A1718306516742&amp;source=hp&amp;ei=1EZrZpflKsrBkPIP1I-r0AI&amp;iflsig=AL9hbdgAAAAAZmtU5H2OMs_LP_WqJRBSL43JctiNkBmr&amp;ved=0ahUKEwiXn6zMptmGAxXKIEQIHdTHCioQ4dUDCBc&amp;uact=5&amp;oq=u.s.+cellular+acquired&amp;gs_lp=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&amp;sclient=gws-wiz">slight lift </a>from T-Mobile&rsquo;s (NASDAQ:<a href="https://investorplace.com/stock-quotes/tmus-stock-quote/">TMUS</a>) recent acquisition of US Cellular (NYSE:<a href="https://investorplace.com/stock-quotes/usm-stock-quote/">USM</a>), as Verizon will have one less low-cost carrier with which to compete.



Additionally, despite Verizon&rsquo;s price hikes, its<a href="https://www.morningstar.com/stocks/after-earnings-is-verizon-stock-buy-sell-or-fairly-valued-4"> customer losses actually slowed</a> in Q1 versus the same period a year earlier. Another important factor for income investors is that the company&rsquo;s dividend is fairly secure, as it spent 60% of its free cash flow on dividends last year, and it is steadily reducing its debt.



Finally, over the longer term, Verizon could benefit from charging its customers extra for AI-related services, and <a href="https://finance.yahoo.com/quote/VZ/key-statistics/">it has a very low forward </a>price-to-earnings ratio of 8.6 times. Given all of these points, I view Verizon as one of the best dividend stocks to buy.



<h2>Molson Coors (TAP)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/TAP1600-300x169.jpg" alt="Molson Coors (TAP) logo on a web browser magnified by a magnifying glass"><div>Source: OleksandrShnuryk / Shutterstock.com</div></div>Molson Coors (NYSE:<a href="https://investorplace.com/stock-quotes/tap-stock-quote/">TAP</a>) has a rather significant, attractive forward dividend yield of 3.45%. For some unknown reason, TAP stock sold off sharply after it reported very strong Q1 results on April 30.



The company&rsquo;s sales <a href="https://seekingalpha.com/pr/19704708-molson-coors-beverage-company-reports-2024-first-quarter-results?hasComeFromMpArticle=false&amp;source=content_type%253Areact%257Csection%253Amain_content%257Cbutton%253Abody_link%257Cfirst_level_url%253Anews">jumped 10.6%</a> versus the same period a year earlier to $2.6 billion, while its earnings before income taxes soared 37.4% year-over-year to a robust $320.6 million. In America, its income before taxes soared 160.5% YOY. 



Molson&rsquo;s growth is likely to slow in future quarters as its comparisons get tougher. That&rsquo;s because it will lap the huge increase in its U.S. customer base that occurred in the wake of political/cultural controversies that ensnared one of its top competitors, Anheuser-Busch (NYSE:<a href="https://investorplace.com/stock-quotes/bud-stock-quote/">BUD</a>). Still, I believe that Molson will be able to retain many of the new customers that it obtained as a result of this factor since consumers tend to be &ldquo;creatures of habit.&rdquo;



Molson Coors can also benefit from its increased emphasis on premium alcohol. There&rsquo;s a good chance that this strategy will raise the company&rsquo;s margins and profits over the longer term since consumers tend to be willing to pay much more for premium products. And there are some signs that its premium products have already become more popular, as it obtained 28% of its revenue from these offerings in 2022, up from 23% in 2019.



TAP stock <a href="https://finance.yahoo.com/quote/TAP/key-statistics/">has a very low forward </a>price-earnings ratio of 9.2 times. 



<h2>Citi (C)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/10/citigroup-c-stock-300x169.jpg" alt="A Citibank (C) sign hangs on a Citibank office in Hong Kong. Citigroup layoffs"><div>Source: TungCheung / Shutterstock.com</div></div>Citi (NYSE:<a href="https://investorplace.com/stock-quotes/c-stock-quote/">C</a>) has a fairly high dividend yield of 3.5%. The bank <a href="https://www.euromoney.com/article/2bpje846ygbe3t8o0npc1/awards/awards-for-excellence/the-worlds-best-investment-bank-in-the-emerging-markets-2023-citi">has rather elevated exposure to</a> emerging markets, and emerging markets tend to suffer from <a href="https://www.cnbc.com/2024/04/30/imf-chief-warns-of-emerging-market-risk-with-high-us-interest-rates.html#:~:text=High%20U.S.%20interest%20rates%20traditionally,cause%20much%20tighter%20financial%20conditions.">high U.S. interest rates. </a>That&rsquo;s because high U.S. rates tend to make their debts costlier, while elevated U.S. rates can also cause them to have &ldquo;capital flight&rdquo; issues.&rdquo;



Given these points, Citi&rsquo;s emerging-market profits should increase meaningfully as U.S. rates fall. Perhaps partly because of this point, C stock <a href="https://finance.yahoo.com/quote/C/">rallied 22% between</a> Dec. 13 and June 13.



Also likely to benefit Citi over the longer term, along with all of its large-bank peers, is regulators&rsquo; reported decision <a href="https://seekingalpha.com/news/4108142-fed-looks-to-slash-capital-holding-requirement-for-big-banks-wsj?source=content_type%3Areact%7Csection%3Asummary%7Csection_asset%3Anews_news%7Cfirst_level_url%3Asymbol%7Cbutton%3ATitle%7Clock_status%3ANo%7Cline%3A3">to lower the amount by which</a> they will raise the institutions&rsquo; capital requirements to roughly 10% from the previously planned 20%.



C <a href="https://finance.yahoo.com/quote/C/key-statistics/">stock has a low forward</a> price-earnings ratio of 10.4 times. while analysts, on average, <a href="https://finance.yahoo.com/quote/C/analysis/">expect its EPS to climb to</a> $6.71 next year from $5.38 in 2024. 



On the date of publication, Larry Ramer did not hold (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>
<div>Larry Ramer has conducted research and written articles on U.S. stocks for 15 years. He has been employed by The Fly and Israel&rsquo;s largest business newspaper, Globes. Larry began writing columns for InvestorPlace in 2015. Among his highly successful, contrarian picks have been SMCI, INTC, and MGM. You can reach him on Stocktwits at @larryramer.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
The post <a href="https://investorplace.com/2024/06/the-dividend-delectables-3-stocks-that-will-satisfy-your-hunger-for-income/">The Dividend Delectables: 3 Stocks That Will Satisfy Your Hunger for Income</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

The Dividend Delectables: 3 Stocks That Will Satisfy Your Hunger for Income

Top 3 consumer staple targets for short sellers in May

Food and beverage stocks gain as investors take a breather from Nvidia, Bitcoin, and AI plays

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Income-oriented investors love finding <a href="https://investorplace.com/stock-types/dividend-stocks/">dividend stocks</a> to buy now. That&rsquo;s particularly true when those stocks are on sale, as many continue to be. However, heading into summer, many things make risk-averse investors cautious about buying equities.&nbsp;&nbsp;



Still, if the CME Group FedWatch Tool is correct, the next direction that interest rates will move is down. And that move may happen as early as September.&nbsp;



At that time, the belief is that&nbsp;investors will benefit as a wider range of stocks become buyable. And as investors know, the largest gains will go to those who were already in these top-performing stocks. &nbsp;



But which stocks will be those top performers? There are many contenders. To come up with this list, I used a simple stock screener. I looked for stocks with projections for at least 15% stock price growth and a minimum dividend yield of 3%. Based on the results, here are seven dividend stocks to buy now. &nbsp;



<h2>&nbsp;Pfizer (PFE)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/08/pfe-stock-2-300x169.jpg" alt="blue Pfizer logo on the windows of a corporate building PFR stock"><div>Source: photobyphm / Shutterstock.com</div></div>The five-year stock chart for Pfizer (NYSE:<a href="https://investorplace.com/stock-quotes/pfe-stock-quote/">PFE</a>) looks like a traditional&nbsp;bell curve chart. But you really wouldn&rsquo;t want to be an investor on the ends of this one. PFE stock swelled in 2021 and 2022 after the company successfully brought a COVID-19 vaccine to market. 



But the explosive growth from those products is long gone and in 2024, PFE stock is waiting for a catalyst to push the stock higher. That may come from the <a href="https://investorplace.com/2024/06/3-underrated-dividend-stock-machines-to-turbocharge-your-income/" target="_blank">company&rsquo;s pipeline</a>. And this is about more than their <a href="https://investorplace.com/2024/06/3-stocks-to-sell-as-ozempic-surges-in-popularity/" target="_blank">struggles in the weight loss arena</a>.&nbsp;



Pfizer is leading the way in areas like <a href="https://www.pfizer.com/science/innovation/mrna-technology" target="_blank">mRNA technology</a> and <a href="https://www.pfizer.com/science/innovation/precision-medicine" target="_blank">precision medicine</a>. The breakthroughs may still be years away. But analysts are beginning to send the message that PFE stock is undervalued. Nine of 26 analysts give it a Strong Buy rating. And a price target of $32.57 would be a 17% stock price gain to go along with a dividend that yields 6.06% and has increased for 15 consecutive years. &nbsp;



<h2>Bristol-Myers Squibb (BMY)</h2>



<a href="https://investorplace.com/wp-content/uploads/2019/04/bmy1.jpg"><img width="300" height="199" src="https://investorplace.com/wp-content/uploads/2019/04/bmy1-300x199.jpg" alt=""></a>I&rsquo;m staying in the biopharmaceutical space with the next stock on this list of dividend stocks to buy now. Bristol-Myers Squibb (NYSE:<a href="https://investorplace.com/stock-quotes/bmy-stock-quote/">BMY</a>) stock is down sharply in 2024. Most of that dip came after the company reported a clunker on the bottom line in its first quarter earnings. <a href="https://investorplace.com/2024/06/3-warren-buffett-stocks-to-buy-now-june-2024/" target="_blank">Posting a negative $4.40 per share</a> is hard for investors to overlook.&nbsp;



However, if you have the time and patience to take a long position, BMY stock is one to consider. Bristol-Myers Squibb has a <a href="https://investorplace.com/2024/06/7-breakthrough-biotech-stocks-for-a-shot-of-portfolio-adrenaline/" target="_blank">significant portfolio of oncology drugs</a>, with the most notable one being its skin cancer drug, Opdivo. And the company&rsquo;s pipeline shows the company is likely to have many more drugs available in the future. &nbsp;



And when you look closer at recent earnings reports, the miss in the second quarter looks like an anomaly. The company is digesting several acquisitions that will boost its portfolio. Nevertheless, investors were in no mood to reward shaky earnings. But analysts remain bullish on the stock which could be ready for a breakthrough. &nbsp;



<h2>Gilead Sciences (GILD)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/10/gild-stock-4-300x169.jpg" alt="A Gilead Sciences (GILD) sign at the company headquarters in Silicon Valley, California."><div>Source: Sundry Photography / Shutterstock.com</div></div>The last biopharma name on this list is Gilead Sciences (NASDAQ:<a href="https://investorplace.com/stock-quotes/gild-stock-quote/">GILD</a>). Recent news illustrates to investors how quickly the fortune of these companies can change. GILD stock surged 10% higher upon news that the company&rsquo;s Phase 3 injectable HIV drug lenacapavir was found <a href="https://www.gilead.com/news-and-press/press-room/press-releases/2024/6/gileads-twiceyearly-lenacapavir-demonstrated-100-efficacy-and-superiority-to-daily-truvada-for-hiv-prevention" target="_blank">100% effective</a> in preventing the infection in cisgender women in recent trials. To say a success rate of 100% is rare would be an understatement. &nbsp;



The stock came back to earth a little. This is most likely due to the realization that it will take some time before Gilead can submit the drug to the U.S. Food &amp; Drug Administration (FDA) for approval. &nbsp;



Gilead is also digesting an acquisition, CymaBay. That will <a href="https://s29.q4cdn.com/585078350/files/doc_financials/2024/q1/GILD-Q124-Earnings-Presentation-25-April-2024.pdf" target="_blank">drag down earnings in 2024</a>. But the company expects the acquisition to be accretive to earnings by 2026. High-yield dividend stocks can sometimes require patience. But that patience could be rewarded with a stock that offers a 4.5% dividend yield while you wait. &nbsp;



<h2>United Parcel Service (UPS)&nbsp;</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/06/ups-1600-1-300x169.png" alt="United Parcel Service (UPS) truck on Interstate in the American West. UPS stock."><div>Source: sladkozaponi / Shutterstock</div></div>United Parcel Service (NYSE:<a href="https://investorplace.com/stock-quotes/ups-stock-quote/">UPS</a>) is an easy choice as one of the dividend stocks to buy now in expectation of lower rates. UPS stock is down about 13% for the year after the company reported lower sequential revenue as <a href="https://investors.ups.com/news-events/press-releases/detail/2119/ups-releases-1q-2024-earnings" target="_blank">volume was down in every category</a> (U.S., International, and Supply Chain). &nbsp;



However, the company did say it saw improvement throughout the first quarter. Furthermore, it expects <a href="https://investorplace.com/2024/06/the-dividend-doyens-7-stocks-that-will-enrich-your-income-portfolio/" target="_blank">volume and revenue to return to growth</a> in future quarters. &nbsp;



The question for investors is whether they should buy the dip in UPS stock. A forward price-to-earnings (P/E) ratio of 16.4% is reasonable. And investors will get a dividend that yields 4.5% and significantly pays $6.52 per share. The payout ratio of over 90% may be concerning with debt that is at 10 year highs. But the company has increased its dividend for 15 years, and with a little help from the Fed, that dividend looks safe. &nbsp;



<h2>Energy Transfer (ET)&nbsp;</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/06/energy-transfer-et-1600-300x169.jpg" alt="A magnifying glass zooms in on the website for Energy Transfer (ET)."><div>Source: Casimiro PT / Shutterstock.com</div></div><a href="https://investorplace.com/industries/energy/">Energy stocks</a> that are sensitive to the price of oil have not fared well in 2024. Fortunately, that&rsquo;s not the case with Energy Transfer (NYSE:<a href="https://investorplace.com/stock-quotes/et-stock-quote/">ET</a>). &nbsp;



The midstream company provides an essential network of pipelines and terminals to keep oil and natural gas flowing. That means its business model is not that sensitive to oil prices. You can see that by looking at the five-year ET stock chart which has shown a steady move upward. &nbsp;



But the stock may still be undervalued. What investors may not be pricing into ET stock is the demand for natural gas that will be driven by data centers. This demand is still in its early stages and is coming from both artificial intelligence (AI) and cloud computing. &nbsp;



As of the market close on June 20, 2024, analysts are forecasting 13.9% earnings growth and a 22% increase in the company&rsquo;s stock price. When you add in the company&rsquo;s status as a <a href="https://investorplace.com/2024/06/uncover-the-best-kept-dividend-secrets-3-stocks-yielding-over-7/" target="_blank">master limited partnership (MLP)</a> with a dividend that yields 8.12% and its forward P/E of around 10x, you can see why its one of the dividend stocks to buy now. &nbsp;



<h2>Vale (VALE)&nbsp;</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/08/vale-1600-300x169.jpg" alt="the Vale logo displayed on a mobile phone with the company's webpage in the background"><div>Source: rafapress / Shutterstock.com</div></div>Why is Vale (NYSE:<a href="https://investorplace.com/stock-quotes/vale-stock-quote/">VALE</a>) down 29.5% in 2024? That has to do with steel prices which have been beaten up as the market is flooded with cheap Chinese steel. However, if the Biden administration has its way, there will be higher tariffs coming on imported steel. &nbsp;



That would be bullish for a company like Vale that provides the iron ore that is needed by steelmakers. The company reported its <a href="https://investorplace.com/2024/06/3-high-dividend-yield-stocks-under-20-that-can-double-in-2025/" target="_blank">highest level of iron ore production since 2019</a> in the first quarter. &nbsp;



But that&rsquo;s not the only reason that analysts see the potential for a 46% increase in the VALE stock price. That&rsquo;s also due to the fact that Vale mines copper. Demand for copper is expected to soar in future years, and data centers will be a significant reason why. &nbsp;



This expected demand makes VALE stock look seriously undervalued with a forward P/E of 6x. And the company has a particularly juicy dividend yield at 10.45%. &nbsp;



<h2>Molson Coors (TAP)&nbsp;</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/TAP1600-300x169.jpg" alt="Molson Coors (TAP) logo on a web browser magnified by a magnifying glass"><div>Source: OleksandrShnuryk / Shutterstock.com</div></div>Molson Coors (NYSE:<a href="https://investorplace.com/stock-quotes/tap-stock-quote/">TAP</a>) is home to many iconic beer brands like Coors and Miller Lite. The company was a beneficiary of the 2023 boycott of the Bud Light brand. Now investors are hoping for an encore. But after a first quarter earnings report that saw the company beating on the top and bottom lines as well as affirming its guidance, TAP stock is down 24% in the three months ending June 20, 2024.&nbsp;



The reason may be in part due to concerns about declining demand due to the popularity of GLP-1 medications. When you combine that with the fact that Bud Light is expected to make a recovery, it&rsquo;s fair to wonder where the growth will come from. The answer may come from the company&rsquo;s shift to focus on its premium brands. &nbsp;



But this is still an attractively valued stock at just 8.8x forward earnings. Analysts give TAP stock a 28.5% upside with a dividend yield of 3.48%. &nbsp;



On the date of publication, Chris Markoch did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com <a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<div>Chris Markoch is a freelance financial copywriter who has been covering the market for over five years. He has been writing for InvestorPlace since 2019.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
The post <a href="https://investorplace.com/2024/06/7-dividend-stocks-to-buy-now-june-2024/">7 Dividend Stocks to Buy Now: June 2024 </a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

7 Dividend Stocks to Buy Now: June 2024

Anheuser-Busch InBev gains after UBS points to attractive cash flow potential

Goldman's top 50 high Sharpe Ratio stocks

Top performers in S&P500 consumer staples fund - Costco and Walmart

Hedge funds betting against staples going into Q3

Near 52-Week Lows, Molson Coors Beverage Offers A Compelling Value And Income Play

ADBE

AKAM

BLDR

CMCSA

COST

CSCO

DLTR

EPAM

FARM

FSTA

FTNT

GILD

HAIN

HEINY

HOLX

INTC

KEYS

MDLZ

MNST

NDSN

PSCC

RSPS

SMPL

TMUS

TRMB

VALE

VRSN

VTRS

WYNN

XLRE

Press Releases

FSD Pharma's Stake In Functional Beverage, UNBUZZD™, Is A Transformational Asset…Here's Why

FSD Pharma: A Compelling Value Proposition As UNBUZZD™ Positions To Dominate The Alcohol-Detox Functional Beverage Market

Entertainment

Barmen 1873 Bourbon and Country Superstar Lainey Wilson Collaborate for the Hold My Bourbon Bar Pop-Up in Nashville

Molson Coors Beverage Company to Webcast 2024 First Quarter Earnings Conference Call

Breathalyzer Market Expands with Tech Advances and Stricter Alcohol Laws

Breathalyzer Market Booms with Technological Advances; Key to Reducing Alcohol-Related Road Deaths

Molson Coors Beverage Company Reports 2024 First Quarter Results

Molson Coors Beverage Company Announces Regular Quarterly Dividend

Molson Coors Beverage Company Announces Proposed Public Offering of Euro-Denominated Senior Notes

Molson Coors Beverage Company Announces Pricing of its Public Offering of Euro-Denominated Senior Notes

AMZN

BLOZF

CAPITAL

CSE:BLO

CSE:HUGE

HUGE

MGPI

TSX:TPX

TSX:TPX.A

TSX:TPX.B

Ambev S.A. American Depositary Shares (Each representing 1 Common Share)

Ambev

Anheuser-Busch Inbev SA Sponsored ADR (Belgium)

Anheuser-Busch InBev

Compania Cervecerias Unidas, S.A. Common Stock

United Breweries Co

Boston Beer Company, Inc. (The) Common Stock

Boston Beer Co

Barclays

Citigroup

B of A Securities

JP Morgan

Molson Coors Brewing

골드만삭스(Goldman Sachs)의 분석가 본니 헤르조그(Bonnie Herzog)는 최근 베버리지 바이트(Beverage Bytes)의 설문조사에서 맥주 유통업체들로부터 얻은 피드백을 바탕으로 몰슨 쿠어스 베버리지(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAP#NYSE">TAP</a>)와 콘스텔레이션 브랜드(Constellation Brands Inc) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STZ#NYSE">STZ</a>)에 대한 판단을 좀 더 긍정적이고, 보스톤 비어 컴퍼니(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAM#NYSE">SAM</a>)에 대한 판단을 부정적으로 바꿨다.
이 분석가는 몰슨 쿠어스 베버리지의 주식평가를 <a href="https://www.benzinga.com/quote/TAP/analyst-ratings" target="_blank" rel="noreferrer noopener">중립 에서 매수로</a> 상향 조정했으며, 목표 주가도 66달러에서 75달러로 상향 조정했다.
헤르조그는 유통업체들이 TAP가 봄 선반 재설정의 큰 승자가 될 것으로 예상하고, 평균적으로 한 자릿수 중반의 선반 공간 비율을 점진적으로 확보할 것으로 기대한다는 점을 고려하면 긍정적인 위험/보상을 본다.
더 많은 유통업체들이 밀러 라이트(Miller Lite) 및 쿠어스 라이트(Coors Light)의 점유율 강화를 보고 있으며, 거의 80%의 유통업체들가 해당 브랜드가 점유율을 유지할 것으로 기대하고 있다고 그가 말했다.
이 분석가는 유통업체들의 78%가 3월에 TAP 브랜드의 재고를 더 많이 보유하고 있었으며 이는 TAP가 봄 재설정을 앞두고 1분기에 예상보다 더 많이 출하했을 수 있음을 시사한다.
그는 미주 지역의 출하량/고갈 성장에 대한 개선된 전망을 반영하여 TAP의 1분기 실적이 양호한 것으로 예상하고 있다.
이 분석가는 TAP의 시장 점유율 순풍이 현재 시장이 평가하는 것보다 더 지속 가능하다는 것이 입증됨에 따라 주식이 더 높게 재평가될 것으로 예상한다.
이 분석가는 콘스텔레이션 브랜드 주식에 대해 4월 11일에 발표될 4분기 실적을 앞두고 290달러의 목표주가와 <a href="https://www.benzinga.com/quote/STZ/analyst-ratings" target="_blank" rel="noreferrer noopener">매수 평가</a>를 재확인했다.
그는 STZ의 맥주 거래량 트렌드가 견고하며, 이번 봄에 추가로 선반과 쿨러 공간을 확보하는 데 가장 큰 수혜자가 될 것으로 예상되기 때문에 잠재적인 매출과 순익 선점이 가능할 것으로 보고 있다.
이 분석가의 긍정적인 견해는 강력한 소비자 수요, 유리한 인구 통계적 트렌드, 강력하고 명확한 브랜드 포지셔닝으로 인해 모델로(Modelo)에 대한 장기적인 성장 여정을 지지한다.
그는 STZ의 강력한 혁신으로 인해 역사적으로 30%였던 생산량 증가율이 향후 5년 동안 최대 40%까지 증가할 것으로 예상한다.
이 분석가는 모델로가 이끄는 핵심 맥주 브랜드를 통해 매력적인 성장을 이룰 수 있을 만큼 STZ의 사업에서 충분한 모멘텀을 계속해서 확인하고 있다. STZ는 그가 선호하는 최고의 주식 중 하나이다.
그는 보스톤 비어의 주식에 대한 평가를 <a href="https://www.benzinga.com/quote/SAM/analyst-ratings" target="_blank" rel="noreferrer noopener">매도로</a> 재확인했으며, 목표 주가는 257달러에서 250달러로 하향 조정했다.
이 분석가에 따르면 유통업체들은 새로운 경쟁업체들이 하드 티(hard tea) 카테고리에 넘쳐나면서 지난 몇 달 동안 트위스티드 티(Twisted Tea)의 모멘텀이 둔화되기 시작했다고 보고했다.
트위스티드 티(Twisted Tea)에 대한 낙관적인 전망에도 불구하고, 트위스티드 티가 트룰리(Truly)의 손실을 상쇄할 만큼 충분한 가치가 있는지에 대한 불확실성을 고려할 때, SAM의 리스크보상은 여전히 부정적인 쪽으로 기울어져 있다는 점을 이 분석가는 지적했다.
그는 유통사들이 SAM 제품의 재고를 계속해서 줄이고 있으며 봄 초기화 기간 동안 선반/쿨러 공간을 더 적게 할당할 것으로 기대한다.
따라서 이 분석가는 1분기의 회계연도 24/24/25년간의 주당 순이익 예측치를 각각 -$0.28/-$0.58/-$0.46, 즉 $0.11/$9.72/$12.63으로 하향 조정했다.
그는 지속적인 톱라인 턴어라운드 스토리의 징후가 더 많이 나타날 때까지 단기적으로 주식에 대한 부정적인 위험/보상이 더 많다고 본다.
주가 움직임: 화요일, SAM 주식은 1.92% 하락한 291.31달러에 마감했다.
사진 제공: 셔터스톡

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Molson Coors Beverage

News

Latest news for Molson Coors Beverage (NYSE:TAP) Stock

Wednesday, April 10, 2024

People Also Watch